-
1.发明申请COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER 审中-公开ERA +配体和HISTONE脱乙酰酶抑制剂治疗癌症的联合公开(公告)号：US20080242648A1
公开(公告)日：2008-10-02
申请号：US11938130
申请日：2007-11-09
IPC分类号： A61K31/565 , A61K31/4406 , A61K31/164 , A61P35/00 , A61K31/506
CPC分类号： A61K31/165 , A61K31/335 , A61K31/44 , A61K45/06 , A61K2300/00
摘要： The present embodiments relate to compositions and methods of treatment of cancer. More particularly, the present embodiments relate to the combination of an ERα+ ligand with an HDACi for the treatment of cancer, methods of treating cancer and pharmaceutical compositions for treating cancer.
摘要翻译： 本实施方案涉及治疗癌症的组合物和方法。 更具体地，本实施方案涉及ERalpha +配体与用于治疗癌症的HDACi的组合，治疗癌症的方法和用于治疗癌症的药物组合物。
-
公开(公告)号：US09579363B2
公开(公告)日：2017-02-28
申请号：US14723701
申请日：2015-05-28
CPC分类号： A61K38/2221 , C07K14/64 , A61K2300/00
摘要： The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.
摘要翻译： 本公开涉及通过急性干预减少代偿失调的方法，包括患有急性失代偿性心力衰竭的受试者。 特别地，本公开提供了通过施用药学有效量的松弛素治疗急性心脏代偿失调的方法。
-
公开(公告)号：US09205132B2
公开(公告)日：2015-12-08
申请号：US13784963
申请日：2013-03-05
CPC分类号： A61K38/2221 , C07K14/64 , A61K2300/00
摘要： The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.
摘要翻译： 本公开涉及通过急性干预减少代偿失调的方法，包括患有急性失代偿性心力衰竭的受试者。 特别地，本公开提供了通过施用药学有效量的松弛素治疗急性心脏代偿失调的方法。
-
公开(公告)号：US08796211B2
公开(公告)日：2014-08-05
申请号：US13088132
申请日：2011-04-15
申请人： Martha Jo Whitehouse
发明人： Martha Jo Whitehouse
IPC分类号： A61K38/18
CPC分类号： A61K38/1825 , A61K2300/00
摘要： The present invention provides a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.
摘要翻译： 本发明提供在药学上可接受的载体中包含0.2μg/ kg至48μg/ kg的SEQ ID NO：2的FGF-2或其血管生成活性片段或突变蛋白的单位剂量组合物。 还提供了一种用于治疗人类患者冠状动脉疾病的方法，包括向所述患者的一个或多个冠状动脉血管或外周静脉施用安全和血管生成有效剂量的重组FGF-2或血管生成活性片段或突变蛋白 其中。 还提供了药物组合物，其在治疗有效的载体中包含治疗有效量的单独或与肝素组合的FGF-2。
-
5.发明授权公开(公告)号：US07186407B2
公开(公告)日：2007-03-06
申请号：US10845911
申请日：2004-05-14
申请人： Martha Jo Whitehouse
发明人： Martha Jo Whitehouse
CPC分类号： C07K14/50 , A61K38/1825 , A61K2300/00
摘要： Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective amount of FGF-2 and a pharmaceutically acceptable carrier are also provided. The methods of the invention to treat peripheral artery disease and claudication comprise administering at least a single dose of a pharmaceutical composition comprising the FGF, such as FGF-2, via intra-arterial, intravenous, or intramuscular infusion to the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.
摘要翻译： 提供了治疗患者外周动脉疾病的组合物和方法。 组合物包含重组成纤维细胞生长因子-2。 以治疗有效量施用成纤维细胞生长因子如FGF-2，以治疗或预防外周动脉疾病，包括跛行和严重肢体缺血。 还提供了包含治疗有效量的FGF-2和药学上可接受的载体的药物组合物。 本发明治疗外周动脉疾病和跛行的方法包括通过动脉内，静脉内或肌肉内输注至少单一剂量的包含FGF的药物组合物，例如FGF-2。 已经认识到，多次给药可能导致增加的益处，包括间歇给药。
-
公开(公告)号：US20140005112A1
公开(公告)日：2014-01-02
申请号：US13939648
申请日：2013-07-11
IPC分类号： A61K38/22
CPC分类号： A61K38/2221 , A61K9/0019 , C07K14/64 , A61K2300/00
摘要： The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin.
摘要翻译： 本公开涉及治疗患有慢性心力衰竭的人类受试者的方法。 本文描述的方法使用松弛素的施用。
-
公开(公告)号：US20120040902A1
公开(公告)日：2012-02-16
申请号：US13242012
申请日：2011-09-23
CPC分类号： A61K38/2221 , C07K14/64 , A61K2300/00
摘要： The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.
摘要翻译： 本公开涉及通过急性干预减少代偿失调的方法，包括患有急性失代偿性心力衰竭的受试者。 特别地，本公开提供了通过施用药学有效量的松弛素治疗急性心脏代偿失调的方法。
-
公开(公告)号：US20120289464A1
公开(公告)日：2012-11-15
申请号：US13088132
申请日：2011-04-15
申请人： Martha Jo Whitehouse
发明人： Martha Jo Whitehouse
CPC分类号： A61K38/1825 , A61K2300/00
摘要： The present invention provides a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.
摘要翻译： 本发明提供在药学上可接受的载体中包含0.2μg/ kg至48μg/ kg的SEQ ID NO：2的FGF-2或其血管生成活性片段或突变蛋白的单位剂量组合物。 还提供了一种用于治疗人类患者冠状动脉疾病的方法，包括向所述患者的一个或多个冠状动脉血管或外周静脉施用安全和血管生成有效剂量的重组FGF-2或血管生成活性片段或突变蛋白 其中。 还提供了药物组合物，其在治疗有效的载体中包含治疗有效量的单独或与肝素组合的FGF-2。
-
公开(公告)号：US20100048475A1
公开(公告)日：2010-02-25
申请号：US12467214
申请日：2009-05-15
CPC分类号： A61K38/2221 , C07K14/64 , A61K2300/00
摘要： The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.
摘要翻译： 本公开涉及通过急性干预减少代偿失调的方法，包括患有急性失代偿性心力衰竭的受试者。 特别地，本公开提供了通过施用药学有效量的松弛素治疗急性心脏代偿失调的方法。
-
公开(公告)号：US06440934B1
公开(公告)日：2002-08-27
申请号：US09385114
申请日：1999-08-27
申请人： Martha Jo Whitehouse
发明人： Martha Jo Whitehouse
IPC分类号： A61K3800
CPC分类号： A61K38/1825 , A61K2300/00
摘要： The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 &mgr;g/kg to 48 &mgr;g/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts six months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.
摘要翻译： 本发明具有多个方面。 特别地，在一个方面，本发明涉及包含0.2μg/ kg至48μg/ kg的SEQ ID NO：2的FGF-2或其药学上可接受的血管生成活性片段或突变蛋白的单位剂量组合物 可接受的载体 另一方面，本发明涉及一种治疗冠状动脉疾病的人类患者的方法，其包括对需要治疗冠状动脉疾病的人类患者的一个或多个冠状动脉血管或外周静脉施用安全和血管生成 有效剂量的重组FGF-2或其血管生成活性片段或突变蛋白。 本发明的单一单位剂量组合物在需要再治疗前6个月的人CAD患者中提供血管生成作用。 另一方面，本发明涉及优化患者安全性的给药方法。 在该实施方案中，流体，肝素和/或输注速率都起作用。 在另一方面，本发明涉及药物组合物，其在治疗有效的载体中包含治疗有效量的单独或与肝素组合的FGF-2。 效益的幅度和持续时间是意想不到的; 另外有利于IV路线是意想不到的。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.115 秒)
